{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004050","form_type":"8-K","ticker":"ANNX","cik":"0001528115","company_name":"Annexon, Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.397578+00:00","generated_at":"2026-06-20T17:46:17.553761+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Annexon prioritizes 4 flagship complement programs; GBS Phase 3 enrollment expanded to 220 patients","bullets":["ANX005 Phase 3 in GBS expanded to 220 patients; pivotal data expected H1 2024.","ANX005 Phase 2/3 pivotal in Huntington's to initiate in 2023.","ANX007 Phase 2 in geographic atrophy on track for initial data mid-2023.","Cash $269.5M as of Sep 30, 2022; operating runway updated to into 2025.","Deprioritizing wAIHA; advancing ANX1502 (oral small molecule) into MAD study H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004050","json":"https://secwatch.observer/filing/0001193125-23-004050.json","markdown":"https://secwatch.observer/filing/0001193125-23-004050.md","text":"https://secwatch.observer/filing/0001193125-23-004050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523004050/0001193125-23-004050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528115/000119312523004050/d422908d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:46:17.553761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}